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Abstract
Background: Although BCG has been found to impart protection against leprosy in many populations, the utility of repeat
or booster BCG vaccinations is still unclear. When a policy of giving a second BCG dose to school children in Brazil was
introduced, a trial was conducted to assess its impact against tuberculosis, and a leprosy component was then undertaken
in parallel. Objective: to estimate the protection against leprosy imparted by a second dose of BCG given to schoolchildren.
Methods and Findings: This is a cluster randomised community trial, with 6 years and 8 months of follow-up. Study site:
City of Manaus, Amazon region, a leprosy-endemic area in Brazil. Participants: 99,770 school children with neonatal BCG
(aged 7–14 years at baseline), of whom 42,662 were in the intervention arm (revaccination). Intervention: BCG given by
intradermal injection. Main outcome: Leprosy (all clinical forms). Results: The incidence rate ratio of leprosy in the
intervention over the control arm within the follow-up, in schoolchildren with neonatal BCG, controlled for potential
confounders and adjusted for clustering, was 0.99 (95% confidence interval: 0.68 to 1.45).
Conclusions/Significance: There was no evidence of protection conferred by the second dose of BCG vaccination in school
children against leprosy during the trial follow-up. These results point to a need to consider the effectiveness of the current
policy of BCG vaccination of contacts of leprosy cases in Brazilian Amazon region.
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Introduction
BCG vaccination is given routinely to neonates to prevent
tuberculosis in Brazil and in most of the world. BCG also protects
against leprosy, with estimates of protection ranging from 20% to
90% [1,2]. In Brazil, in addition to routine BCG vaccination at
birth to prevent tuberculosis, BCG is officially recommended for
household contacts of leprosy cases. In 1994 the Brazilian Ministry
of Health expanded its tuberculosis control policy to recommend
the routine BCG vaccination of school age children (around 7–
14 years old). Given the high coverage of neonatal vaccination,
this was effectively revaccination for most children. A large cluster
randomised trial (BCG-REVAC) was started in 1996 to assess the
effectiveness against tuberculosis of BCG vaccination of school-
children [3,4]. One of the trial sites was the city of Manaus, which
is also endemic for leprosy. In this city the trial objective was then
expanded to estimate the effectiveness on leprosy. This paper
reports the results of the BCG-REVAC trial in preventing leprosy
based on follow-up from January 1999 to August 2006.
Methods
Details of the methodology of the BCG-REVAC trial and of the
leprosy component have been published elsewhere (regarding trial
co-ordination, screening to detect leprosy cases before the trial,
and sample size) [4,5]. A CONSORT checklist is available in Text
S1. We summarise here relevant methodological aspects.
The main objective of the leprosy component of the BCG-
REVAC trial was to estimate the protection against all forms of
leprosy given by one dose of BCG under routine conditions to
schoolchildren aged 7–14 years in a population with coverage of
neonatal BCG of about 89%. Our original hypothesis was that
BCG revaccination would cause 50% reduction in incidence,
based on the estimate observed in the trial in Malawi [6]. This is a
vaccine effectiveness, pragmatic trial [7], rather than an efficacy
trial. The study design attempted to reproduce the routine
implementation of the policy of BCG vaccination of schoolchil-
dren according to the 1994 recommendation.
The study site was the city of Manaus, in Amazonas State of
Brazil, with about 1,500,000 inhabitants in 2002. The city is
divided into 56 administrative districts, which in turn are grouped
into 6 geographical areas (North, East, South, West, Centre West
and Centre South). The new case detection rate (NCDR) has been
around 6.5 cases per 10,000 per year of leprosy since the 1990s. In
1997 the NCDR was 6.6 (814 cases) in the total population and
4.9 (110 cases) in children aged 7–14 years. The trial study
population was schoolchildren residing in the city, aged 7–
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implementation in 1998 (year of birth between 1984 and 1991).
No child was excluded on the basis of previous history of
tuberculosis or leprosy, mirroring the official recommendation for
BCG vaccination to schoolchildren.
Randomisation. There are several reasons to do randomisation
at cluster level in studies on infectious diseases [8]. In this trial, the
main reason was operational: a list of schools with approximate
numbers of students, but not names, was available. Without a list
of student’s names, individual randomization would be much
harder given the very large number of children involved. The
decision also considered the following advantages of cluster
randomisation in this case: intervention (vaccination) more likely
to be acceptable, as all schoolchildren within the same school
would be allocated to receive or not to receive vaccination; simpler
execution; large number of randomisation units (schools) expected
to result in similar comparable allocation groups. Furthermore,
since the recommendation was to vaccinate schoolchildren,
schools represent the settings where this intervention would
naturally be implemented in a real campaign.
There was no previous study on leprosy in which intra-class
correlation (ICC) had been estimated, and ICC estimated by this
study before the trial follow-up resulted in a negative value [5],
which was interpreted as suggestive of no effect of clustering [9].
Therefore, although this was a cluster randomised trial, the initial
sample size estimation made no allowance for clustering, and it
was estimated 50,000 children in each allocation arm [5], using
formulae in chapter 7 of Friedman et al. [10].
The randomisation followed several steps and was conducted using
a list of schools provided by the local education department, with
estimates of the number of schoolchildren in each school. Only
schools with more than 50 schoolchildren in the target age group and
in the main urban area of Manaus were included. First, the 56
districts were classified into strata according to the incidence of
leprosy and tuberculosis in each district before the trial (1996). If the
leprosy incidence (NCDR) in 1996 in a district was above the rate of
the city as a whole, then it was categorised as ‘‘above’’=1, otherwise
(below the city rate) as ‘‘below’’=0. The same procedurewas used for
tuberculosis, ‘‘above’’ or ‘‘below’’ the city rate. The 56 districts were
thus grouped into 5 strata of incidence of leprosy and tuberculosis:
four combinations of rate of tuberculosis and leprosy (above/above,
above/below, below/above and below/below the rate of the city,
respectively), and a fifth category with the districts with unavailable
data on leprosy and tuberculosis. Second, the schools in the list were
sorted by a) greater geographical areas, b) the 5 strata and then c) on
t h ee s t i m a t eo ft h en u m b e ro fs c h o o l c h i l d r e na tt h et a r g e ta g eg r o u p .
Third, within the same geographical areas and 5 strata, the schools
with the closest number of schoolchildren were then taken as a pair.
Fourth, random numbers were generated by computer for each
school, and in each pair the school with the smallest random number
was allocated to the control arm, and the other was allocated to the
intervention arm. When a school had no pair (odd number of schools
in the stratum by geographical area and category on leprosy/
tuberculosis), it was allocated at random (odd number was control,
even number was intervention). The randomisation process was
implemented by two researchers, S.S.C and S.P.
Three hundred and forty five (345) schools from the original list
were used in the randomisation, selected based on number of
students and being located in urban area. The number of
schoolchildren was approximately estimated to be 161,736.
However, subsequent field work showed that some of the
information in the list was inaccurate, and schools in the list were
excluded for several reasons: number of schoolchildren smaller
than 50; school closed during the time of trial implementation;
school mostly included children with special needs. Also, a single
school was listed as two schools because it was based over two sites.
Finally, from the original 345 schools, only 286 were eventually
entered in the trial.
Recruitment
After randomisation, visits to these 286 schools were conducted
between July and October 1998 to collect children’s data,
including BCG scar reading and BCG vaccination. Data were
transcribed from school records, and children were examined to
identify those who had received neonatal BCG vaccination, based
on BCG scar.
Intervention
Children in the schools allocated to vaccination received 0.1 ml
of lyophilised BCG produced in Brazil, Moreau strain, adminis-
tered by intradermal injection [4]. Four different batches were
used but vaccination in any one school was done with a single
batch. Vaccination began in September and finished in December
1998. Children in the control arm did not receive a placebo.
Data were collected from 156,331 schoolchildren (nearly 70%
of the estimated population of Manaus aged 7–14 years in 1998),
and 3,893 children were later excluded because they were outside
this age range (see Figure 1). The analysis plan originally proposed
to estimate the vaccine effect in children with either no or one
BCG scar as observed at baseline, consisting of 110,218 children:
51,207 in the intervention arm (allocated to vaccination) of whom
46,997 were vaccinated (92%). Reasons for not vaccinating the
remaining 4,210 children included refusals, withdrawals, and
changes in school [5].
Follow-up
Because most leprosy in Manaus is tuberculoid, which has a
shorter incubation period [11], and the protection of BCG against
leprosy was observed very soon (after 1 year) in some trials [12,13],
the decision was made to start the follow-up from 1
st January 1999
(and to end in August 2006, see analysis). First January 1999
corresponded to more than 2 months after vaccination for nearly
50% of the vaccinated children (range 22–100 days).
Allocation concealment refers to the process of making the
investigators not able to know the randomisation sequence
between the time it is generated and the time a particular code
is allocated to study unit [14]. In our trial, the allocation was done
immediately after the sequence generation, so the allocation was in
effect concealed.
Author Summary
BCG is a vaccine developed and used to protect against
tuberculosis, but it can also protect against leprosy. In
Brazil, children receive BCG at birth, and since 1996 a trial
has been conducted to find out if a second dose of BCG
administered to schoolchildren gives additional protection
against tuberculosis. We use this trial to find out if such
vaccination protects against leprosy. The trial was con-
ducted in the Brazilian Amazon, involving almost 100,000
children aged 7–14 years who had received neonatal BCG.
Half of them received a second dose of BCG at school, and
the other half did not. We followed the children for 6 years
and observed that there were as many new cases of
leprosy in the vaccinated children as in the unvaccinated
children. Therefore, we concluded that a second dose of
BCG given at school age in the Brazilian Amazon offers no
additional protection against leprosy.
BCG Does Not Protect against Leprosy
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Manaus, where the local leprosy control programme and its
surveillance system are located. In the study site, would be very
unusual for a suspected case of leprosy to be identified at school
and referred to the health services for diagnosis and treatment.
Leprosy cases normally go spontaneously to routine health
services, or are referred from primary services to the leprosy
reference centre, as several services have dermatologic clinics.
Therefore, detection rates are not expected to differ systematically
between control and intervention schools.
In order to give blind diagnosis at the reference centre, most
patients (85 out of 91) up to 2001 had their right deltoid area
covered by an adhesive tape on entering the medical offices for
investigation of leprosy the diagnosis, however, after 2001 this
procedure was found to be little used and was then definitely
discontinued. Physicians were also continually asked to refrain
from inquiring about the BCG status until a definitive diagnosis of
leprosy was made, unless the physician has judged it was necessary
to know the BCG status for good clinical practice. Therefore, the
trial can not be considered as being blind, and furthermore the
absence of placebo meant that neither those administering the
interventions, nor the participants were blind to their assignment.
Case diagnosis and classification
Cases were thus classified into multibacillary (MB) and pauciba-
cillary(PB)asreportedinmedicalrecordsandhistopathologyexams,
and diagnosis made following the routine procedures used in the
reference service, based mostly on combination of clinical signs,
baciloscopy and histopathologyand onWHO criteria[15]. Bacillary
index and biopsies are routine procedures for all suspect cases, unless
there are contraindications such as in young children, facial lesions,
and refusal by the patients. Data on anaesthesia, aspects of skin
lesions and thickening nerve are routinely collected during the
clinical examination. Such data on the diagnosis and classification
were thus periodically retrieved as described in the medical records
soonafterthediagnosis,butanydoubtonclassificationanddiagnosis
was discussed with the professionals responsible by the patient or
exam. Cases are routinely classified according to grade of disability
(0=no anaesthesia or deformity in hands or feet, and no eye
problem; grade 1=with anaesthesia but no deformity, or with eye
problem but vision not severely affected; grade 2=visible deformity
or vision severely affected [16]), and this was information was also
retrieved. The difficulty of diagnosing leprosy is well known, and one
way to overcome such difficulties is to categorise the leprosy cases in
‘‘certainty levels’’ based on typical signs [17]. There was an initial
attempt during the first/second year of follow-up to register relevant
signs and symptoms into a standardised questionnaire to be
completed by the doctors responsible by the assistance of each
suspect case, as well as histopathology exams should follow specific
procedures and findings annotated into a standardised form.
However, the completion rate was low and the information from
these forms was not used. There was no independent review panel
for deciding on the final diagnosis of leprosy cases. Given that it is an
effectiveness (pragmatic) trial, which means it was aimed at assessing
vaccine effect under routine conditions, it was decided that all
leprosy cases reported in the surveillance system should be included
Figure 1. Flow of clusters and individual participants through each stage.
doi:10.1371/journal.pntd.0000167.g001
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cases classified into 2 levels of certainty based on laboratory and
clinical presentation: those with confirmed histopathology, or
positive baciloscopy or thickening nerve, versus those without any
of these data. Therefore, we performed sub-group analysis for these
two levels.
Leprosy cases detected by the local surveillance system were
linked to the trial population by matching information from the
notification to records in the trial data-base (date of birth, name of
case and name of the case’s mother) [5]. There were 650 leprosy
cases detected by the local surveillance from 1999 to August 2006
in the target age population and residing in Manaus, of whom 253
cases were identified in the 156,331 total trial population, and 117
cases (out of 253) were among those 92,770 children with one
BCG scar (see Figure 1). In this group, 91.6% of children in
intervention arm (n=42,662) actually received BCG in the trial,
and only 2 children in the control arm (n=50,108) were wrongly
vaccinated (originally enrolled in school in the control arm but
actually attending school in intervention arm).
Surveillance for adverse events. The routine passive surveillance
of adverse events was enhanced. A letter containing information
on BCG adverse events was distributed to all children on the day
of vaccination to motivate parents to take their children to a health
facility if they had a health problem following vaccination.
Teachers in the trial schools and health workers in the reference
medical centres for tuberculosis and leprosy were made aware of
the trial and alerted to possible BCG adverse events. Suspect
adverse events were diagnosed in the health facilities and
treatment provided. This vaccine safety surveillance continued
for 4 months after the end of vaccination.
Ethics
TheBCG-REVACtrialreceived ethicalapprovalbytheBrazilian
National Ethical Committee (CONEP, Comissa ˜o Nacional de E ´tica em
Pesquisa) [5]. The trial is registered with an International Standard
Randomised Controlled Trial Number, ISRCTN07601391 (http://
www.controlled-trials.com/ISRCTN07601391).
Analysis
The mainoutcomeofthe leprosy component ofthis trialconsisted
of leprosy cases diagnosed in the health facilities in Manaus,
expressed as the NCDR of leprosy per 10,000 person years in the
two arms during the trial follow-up. Baseline characteristics of the
population are presented at individual and cluster levels separately
for the intervention and control arms, and for those excluded and
those included in the vaccine effect estimation. No significance test
was used to assess differences on baseline characteristics [18]. All
calculations were based on rates and rate ratios estimated by Poisson
regression. The 95% confidence intervals were based on robust
(‘‘sandwich’’) variance estimator, specifying school (not pair of
schools) as cluster to allow for clustering within schools [19]. Rates
and rate ratios were also adjusted for covariates to correct for any
imbalance between intervention groups, and covariate adjustments
are stated below when describing each analysis.
BCG vaccine protection was estimated as (1-RR)6100, RR
being the ratio of the rate in the intervention arm over the rate in
the control arm, among those 92,770 individuals with one BCG
scar, with intention-to-treat analysis. Statistical analysis was done
in STATA version 7.0.
Departure from protocol
Interim analysis of the leprosy results was not planned.
Originally, the analysis was planned for all leprosy cases involving
those with no or one BCG scar, which was planned to have a
power of 80% to detect a vaccine protection of 50%. This analysis
was conducted in 2003, but not published [20]. However, it was
subsequently recognised that the most important estimate would
be for those with neonatal BCG, rather than for all children
regardless of previous BCG status, because Brazil currently
achieves a high neonatal BCG coverage rate, which means that,
in the near future, most individuals will have received neonatal
BCG. In addition, there was not enough power to assess
heterogeneity of vaccine effect according to one or zero BCG
scar. The decision was therefore made to redo the analysis, among
only those children with one BCG scar at entry, at a time when a
study power of 80% was projected to have been achieved for this
sub-population. Based on the hypothesised rate ratio of 0.5, and
91% coverage in the vaccine arm, this was achieved with the 117
cases detected up to August 2006 [21]. Hence the decision was
made to analyse the cases accumulated up to this time. This paper
therefore reports the estimate for vaccine protection among
children with one BCG scar, that is, effect of re-vaccination. At the
moment of this analysis, the number of cases among those with no
BCG scar was not sufficient for a study power of 80% and thus
vaccine protection was not estimated in this group.
Results
The number of leprosy cases detected in the trial and number of
children are shown in Figure 1. The baseline characteristics of the
two allocation arms were similar regarding gender, age at entry
into the trial (Table 1). A higher proportion of children in
intervention arm were in schools located in areas that had higher
incidence of tuberculosis and leprosy (NCDR) before the trial (bold
numbers in Table 1).
Among those excluded from the analysis for having no BCG
scar reading, or with no scar or .1 scar, the leprosy rates (per
10,000) were 3.07 (95% C.I.: 2.43 to 3.89; 69 cases in 224,605
person years) in the control arm, and 2.80 (95% C.I.: 2.20 to 3.57;
65 cases in 232,016 person years) in the intervention arm. All
results below are restricted to those with one BCG scar.
Description of cases. Among the 117 cases in the population with
1 prior BCG scar, 30 cases were MB and 87 PB. Most cases (112)
had grade 0 (no disability);inthe intervention armtherewere3 cases
with grade 1 and 2 cases with grade 2. Nineteen cases had nerve
thickening (16.2%): 8 (13.1%) in control arm, and 11 (19.6%) in
intervention. Fifty seven cases (48.7%) were confirmed by histopa-
thology: 29 (47.5%) in control arm, and 28 (50.0%) in intervention.
The meanage at diagnosiswas 15.6 years(sd 3.1)incontrol and14.2
(sd 3.0) in intervention. There were 47.5% of male cases in the
control arm (29/61) and 51.8% (29/56) in the intervention arm.
The rates (per 10,000 person-years) of MB cases were 0.36 in
the control arm (14 cases/383,754 person years) and 0.49 in the
intervention arm (16/326,673 person years). For PB the rate was
1.22 in both arms. The rates by calendar year separately and
allocation arm are shown in Table 2. There was a borderline
statistically significant increase in the rate in the intervention arm
in the first year of follow-up (1999), the rate ratio being 2.50 (95%
C.I.: 0.99 to 6.35) (Table 2). This increase in the first year was
observed for PB and MB cases: the rate ratio was 2.63 (95% C.I.:
0.31 to 22.00) for MB cases and 2.91 (95% C.I.: 0.87 to 7.20) for
PB cases, adjusted as in Table 2.
The rate ratio between allocation arms is shown in Table 3,
separately for MB and PB, controlled for study variables and
adjusted for effect of clustering. There was no evidence of
protection by the second dose of BCG during the follow-up period.
For the whole study period, the robust standard error of the
intervention-over-control rate ratios (controlled for the variables as
BCG Does Not Protect against Leprosy
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not adjusted for clustering. We estimated design effect as
(0.18987/0.18581)
2=1.0442. Given that the design effect is
1+(n–1)6ICC, where ICC is the intra-class correlation coefficient
and n is the mean cluster size (=327), the ICC was estimated as
0.00013568.
The rate ratio between those vaccinated and not vaccinated,
regardless of allocation arm (using on-treatment analysis) for the
whole trial follow-up was, for all leprosy cases 0.97 (95% C.I.: 0.67
to 1.41), for MB cases 1.08 (0.54 to 2.15) and PB cases 0.92 (0.59
to 1.43), after controlling for study variables as in Table 3. After
excluding the first year of follow-up, the rate ratio for all leprosy
Table 1. Comparability of the baseline characteristics of the trial population, according to BCG scar.
Baseline Characteristics
Schoolchildren without BCG Scar Reading,
without BCG Scar or .1 Scar (Excluded in
the Analysis of Vaccine Effect)
Schoolchildren with 1 BCG Scar
(Included in the Analysis of Vaccine
Effect)
Control Intervention Control Intervention
Total number 29,350 30,318 50,108 42,662
Median number per school (percentiles 25%–75%) 181 (113–271) 193 (121–265) 302 (209–433) 274 (159–383)
Number of males (%) 14,572 (49.7) 15,232 (50.2) 24,530 (49.0) 20,880 (48.9)
Average percentage of males per school 50.0% 50.0% 48.9% 49.2%
Mean age in years at entry into the trial (SD
a) 11.5 (2.2) 11.3 (2.2) 11.34 (2.11) 11.17 (2.05)
Mean age in years at entry into the trial, per school (SD
a) 11.2 (1.3) 11.0 (1.1) 11.2 (1.3) 11.1 (1.2)
Rates of tuberculosis in 1996
b and number of schoolchildren (%)
14.5 to 125 per 10,000 20,152 (68.7) 19,186 (63.3) 35,436 (70.7) 27,819 (65.2)
131.6 to 618 per 10,000 8,390 (28.6) 11,132 (36.7) 13,875 (27.7) 14,843 (34.8)
Areas without data on tuberculosis rates 808 (2.8) 0 797 (1.6) 0
Rates of leprosy in 1996
c and number of schoolchildren (%)
0 to 4.57 per 10,000 6,539 (22.3) 5,878 (19.4) 11,334 (22.6) 6,924 (16.2)
4.83 to 6.38 per 10,000 7,545 (25.7) 6,967 (23.0) 12,636 (25.2) 9,460 (22.2)
6.52 to 7.33 per 10,000 6,958 (23.7) 5,259 (17.4) 12,215 (24.4) 9,221 (21.6)
7.82 to 10.92 per 10,000 3,572 (12.2) 5,139 (17.0) 6,449 (12.9) 6,685 (15.7)
12.21 to 66.94 per 10,000 4,234 (14.4) 7,075 (23.3) 6,791 (13.6) 10,372 (24.3)
Areas without data on leprosy rates 502 (1.7) 0 683 (1.4) 0
aSD is standard deviation.
bRates of tuberculosis before the trial and geographical areas where schools were located, the two categories correspond to the rate below and above of the city.
cRates of leprosy before the trial and geographical areas where schools were located.
doi:10.1371/journal.pntd.0000167.t001
Table 2. Rates of leprosy separately for calendar year during the follow-up period among those with 1 BCG scar.
Allocation Groups Year of Follow-Up
1999 2000 2001 2002 2003 2004 2005/6
a Total
Intervention
Cases 14 10 548695 6
Person years 42,653 42,643 42,363 42,631 42,625 42,617 70,868 326,673
Rate 610,000 3.28 2.35 1.18 0.94 1.88 1.41 1.27 1.71
Control
Cases 7 9 11 4951 6 6 1
Person years 50,105 50,096 50,086 50,078 50,073 50,065 83,250 383,754
Rate 610,000 1.40 1.80 2.20 0.80 1.80 1.00 1.92 1.59
Rate ratio
b 2.50 1.21 0.41 0.85 1.02 1.18 0.71 0.99
95% C.I. 0.99 to 6.35 0.49 to 3.00 0.13 to 1.32 0.17 to 4.11 0.36 to 2.88 0.33 to 4.28 0.33 to 1.55 0.69 to 1.43
aUntil August 2006.
bBased on Poisson regression with robust variance estimator specifying school as cluster, and controlled for incidence of tuberculosis and NCDR of leprosy in
geographical areas before the trial (all as categorical variables as in Table 1), sex, and year of birth. All estimates excluding 870 school children (being 2 leprosy cases in
control group, 1 in 1999 and other in 2005–6, both PB cases) who had no data for tuberculosis and/or leprosy in geographical area.
doi:10.1371/journal.pntd.0000167.t002
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and for PB cases was 0.71 (0.43 to 1.15).
The rate ratio intervention over control arms, based on cases with
confirmed histopathology, positive baciloscopy or thickening nerve
(n=60) was 1.51 (95% C.I.: 1.04 to 2.19), after control for sex, BCG
scar, year of birth, and the previous rates of leprosy and tuberculosis
in the districts where schools were located. For those with neither
confirmed histopathology, positive baciloscopynor thickening nerve,
but based on clinical judgement on typical skin lesion and presence
of anaesthesia (n=57), it was 1.03 (95% C.I.: 0.76 to 1.39).
Among the total 152,438 individuals enrolled in the study,
47,307 individuals were vaccinated, and 18 cases were reported
with adverse events related to BCG (risk of 3.80 per 10,000). Eight
cases was due to ulcer greater than 1 centimetre, 7 cases had cold
abscess, and the 3 remaining cases had axillary lymph node
enlargement without suppuration, ‘‘hot’’ abscess with suppuration
and nodule in vaccination site. Children without previous BCG
scar had a risk of 3.67 (3 cases/8,176 individuals), and those with 1
BCG scar (revaccination) the risk was of 3.84 (15 cases/39,067),
this corresponded to a risk ratio of 1.05 (95% C.I.: 0.31 to 3.53),
after adjustment for effect of clustering, sex and year of birth.
Discussion
This study found no evidence of protection of the second dose of
BCG against all forms of leprosy among school children within
6 years and 8 months of follow-up. This remained after control-
ling for potential confounders and adjusting for effect of clustering.
The confidence interval of 0.72 to 1.58 (for the all cases and the
whole period, controlled for covariates and adjusted for clustering)
is consistent with a vaccine protection of up to 28% and an
increase in leprosy in those vaccinated up to 58%. We conclude
that the results did not support the original hypothesis of a vaccine
protection of 50%, and additional follow-up is thus not planned.
Table 3. Rate ratios between rate in intervention arm over rate in control arm, among those with 1 BCG scar, whether controlled
for study variables, separately for clinical forms.
Clinical Forms and Follow-Up Period Allocation Group Rate Ratio
a (95% C. I.)
Intervention Control Leprosy rate in 1996 Used as:
5 Categories Continuous
For the whole follow-up period Py
b=326,673; cases=56 Py
b=377,095; cases=59 —
Total cases n =115
Rate ratio, crude estimate adjusted for clustering
c — — 1.10(0.73 to 1.64)
Rate ratio, adjusted for confounders but not for clustering
d — — 0.99(0.69 to 1.43) 1.07(0.74 to 1.54)
Rate ratio, adjusted for confounders and for clustering
e — — 0.99(0.68 to 1.45) 1.07(0.72 to 1.58)
Multibacillary cases n=30 16 14 —
Rate ratio, crude estimate adjusted for clustering
c — — 1.32(0.67 to 2.61)
Rate ratio, adjusted for confounders but not for clustering
d — — 1.39(0.69 to 2.79) 1.33(0.66 to 2.69)
Rate ratio, adjusted for confounders and for clustering
e — — 1.39(0.72 to 2.66) 1.33(0.69 to 2.59)
Paucibacillary cases n=85 45 40 —
Rate ratio, crude estimate adjusted for clustering
c — — 1.00(0.61 to 1.64)
Rate ratio, adjusted for confounders but not for clustering
d — — 0.86(0.56 to 1.33) 0.98(0.64 to 1.51)
Rate ratio, adjusted for confounders and for clustering
e — — 0.86(0.54 to 1.37) 0.98(0.60 to 1.62)
Excluding the first year of follow-up Py
b=284,019; cases=42 Py
b=333,649; cases=53 —
Total cases n =95
Rate ratio, crude estimate adjusted for clustering
c — — 0.91(0.59 to 1.43)
Rate ratio, adjusted for confounders but not for clustering
d — — 0.83(0.55 to 1.24) 0.91(0.61 to 1.37)
Rate ratio, adjusted for confounders and for clustering
e — — 0.83(0.55 to 1.25) 0.91(0.59 to 1.41)
Multibacillary cases n=26 13 13 —
Rate ratio, crude estimate adjusted for clustering
c — — 1.15(0.54 to 2.49)
Rate ratio, adjusted for confounders but not for clustering
d — — 1.28(0.60 to 2.76) 1.30(0.60 to 2.79)
Rate ratio, adjusted for confounders and for clustering
e — — 1.28(0.63 to 2.62) 1.30(0.63 to 2.65)
Paucibacillary cases n=69 29 40 —
Rate ratio, crude estimate adjusted for clustering
c — — 0.84(0.52 to 1.35)
Rate ratio, adjusted for confounders but not for clustering
d — — 0.68(0.42 to 1.10) 0.80(0.49 to 1.30)
Rate ratio, adjusted for confounders and for clustering
e — — 0.68(0.40 to 1.16) 0.80(0.45 to 1.43)
aAll estimates excluding 870 school children (being 2 leprosy cases in control group, 1 in 1999 and other in 2005/6, both PB cases) who had no data for tuberculosis
and/or leprosy in geographical area.
bPy: total person years.
cBased on Poisson regression with robust variance estimator specifying cluster (schools), without controlling for confounders.
d4Based on Poisson regression with robust variance estimator without specifying cluster (not adjusted for clustering effect), and controlled for sex, year of birth,
incidence of tuberculosis (categorical as in Table 1) and NCDR of leprosy (categorical as in table 1 or continuous variable) in geographical areas before the trial.
eThe same to the regression above, but specifying schools as cluster (adjusted for clustering effect).
doi:10.1371/journal.pntd.0000167.t003
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MB and PB cases, but this analysis was not powered to evaluate
protection separately for clinical forms at this duration of follow
up. We can speculate some alternative hypotheses why the
expected protection by revaccination was not observed.
First, differential detection rate. The diagnosis of most leprosy
cases was blind to vaccination status in the first two years, but after
2001 the procedures recommended for blind diagnosis were not
used. However, diagnosis was based on routine procedures as
before the trial, and it is unlikely that special attention was paid to
patients’ revaccination status: BCG history tends to not be
considered in routine procedures in Manaus. It is also unlikely
that patients themselves sought medical attention differentially
according to whether they were vaccinated in the trial. So a
subjective assessment would suggest that distortion of the estimates
due to differential detection rate because of lack of blindness seems
unlikely.
Second, the result could be due to misdiagnosis. The difficulty of
diagnosing leprosy is well known [17]. If patients with other skin
lesions were wrongly diagnosed as having leprosy and were
included in the study, this would lead to an underestimation of the
vaccine effect. However, the quality of diagnosis in the study was
high: most leprosy cases had the typical signs or laboratory
findings of leprosy. This is strengthened by the fact that this study
was based on a reference centre for leprosy diagnosis and
treatment, with very experienced clinicians; and protection did
not increase with certainty of diagnosis. Therefore, it is unlikely
that false positive diagnoses would be responsible for lack of
vaccine effect.
Third, linkage of cases. The linkage was done blind to
vaccination status, and so it is unlikely that any failure in linkage
of cases would be differential. Fourth, this could be due to
imbalances in the baseline characteristics in the comparison
groups or selection bias when defining the study population.
Indeed, the incidence of leprosy (NCDR) in the geographical areas
where vaccinated and control schools were located were
unbalanced, despite the randomisation process. This imbalance
must have been caused from the inaccuracy of the list of schools
used in the randomisation process and the exclusion after
allocation. This unbalance could potentially distort the vaccine
effect, which is why we controlled for sex, age, year of birth, and
previous incidence of tuberculosis and leprosy in the analysis.
Fifth, poor vaccine administration and vaccine storage. The
vaccination was done following routine procedures, however,
temperature was regularly checked and no problems were
detected. Furthermore, vaccine strain, the staff and procedures
used in the trial were similar to used in neonatal vaccination, and
neonatal BCG vaccination was shown to be protective against
leprosy in the cohort study nested on the trial [22]. Therefore,
vaccine administration and vaccine storage were at worst similar
to those which have resulted in protection of 90% in the nested
cohort study for neonatal vaccination.
Sixth, the lack of vaccine effect could not be due to a distortion
caused by vaccination by the trial of individuals in the control arm,
because very few individuals in the control arm among those with
one BCG scar were vaccinated (n=2 of 50,108). BCG vaccination
in schoolchildren was suspended in the study site because of the
trial during the study follow-up, and definitely in the whole
country in 2006. Nevertheless, 312 schoolchildren in Manaus were
reported as wrongly vaccinated in routine in 2002 although none
belonged to the trial population. No other child in the target age
group was reported vaccinated by public health services [23], and
the number of children who received BCG in private services is
negligible, given that it is offered free of charge by public services.
Eighth, the presence of HIV infectionin Manaus. There are no
data on infection, but the annual average number of reported
AIDS cases aged 15–19 years between 2001 and 2004 was 13
cases, with a estimated population in this age group of 182,745 in
2004, therefore HIV infection is expected to be very low and not
have any effect on the vaccine effect observed [23].
The increase in the leprosy rate during the first year of follow-up
in the intervention arm deserves comment. There is some prior
evidence of BCG vaccination increasing the risk of leprosy in the
initial follow up period, probably due to change in disease
progression (‘‘negative effect’’) [24–26]. However, revaccination
was also not protective when the first year of follow-up was
excluded, and the increase in the first year of follow up was not
responsible for the absence of effect observed for the whole period.
How does this result compare to previous studies? Among trials,
in the study in Papua New Guinea the participants received
different number of doses during the trial. However, the reports
did not present vaccine protection or data separately for the
number of doses received, although it was stated that the number
of doses did not affect the vaccine protection [13]. In the last trial
in India (1991), the study participants included those with and
without previous vaccination, but separate data for previous
vaccination were not shown, although it was reported that
previous vaccination did not affect the protection conferred by
the vaccine given by the trial [27]. In contrast, the trial in Malawi
estimated the vaccine protection given by a second dose, and
showed a statistically significant vaccine protection of 50% [6], but
there were several different characteristics, including: different
BCG strain (from Glaxo); screening to remove leprosy cases before
vaccination; randomisation by individual rather than cluster; a mix
of passive and active case detection; and broader age range from
infants to adults. Among case-control studies, two assessed vaccine
effect by number of doses and both showed additional protection
with more than one dose [28,29], but only in one study was a
statistically significant trend of higher protection with increased
number of doses [28]. A recent meta-analysis of BCG vaccination
against leprosy concluded that additional doses offer additional
protection [30]. This meta-analysis also found strong evidence of
heterogeneity between studies. In our oppinion, although there is
indeed some evidence for additional protection, the results are
variable and do not support an unequivocal conclusion for
additional protection by more than one dose in all sites.
Had the follow-up period been longer, would it be possible to
observe vaccine protection in the years to come? There has been a
recent report of BCG protection against tuberculosis lasting for at
least 20 years in Brazil [31]. Indeed, in the last trial in India (1991)
no vaccine protection was observed in the first years, but a
statistically significant result was observed afterwards [24].
Therefore it is theoretically possible that continued follow up will
demonstrate protection in coming years, but it is uncertain that
this would be of public health importance.
BCG revaccination is currently recommended to contacts of
leprosy patients in Brazil [32]. The results of this trial are not
directly applicable to the setting of contacts, as protection of
revaccination might be different given the close exposure in
contacts, but we suggest that the effectiveness of revaccination in
contacts must be evaluated to inform a review of such
recommendation.
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